CN110195069A - 共有抗原构建体和由其制备的疫苗以及使用所述疫苗治疗疟疾的方法 - Google Patents

共有抗原构建体和由其制备的疫苗以及使用所述疫苗治疗疟疾的方法 Download PDF

Info

Publication number
CN110195069A
CN110195069A CN201910279715.8A CN201910279715A CN110195069A CN 110195069 A CN110195069 A CN 110195069A CN 201910279715 A CN201910279715 A CN 201910279715A CN 110195069 A CN110195069 A CN 110195069A
Authority
CN
China
Prior art keywords
seq
acid sequence
nucleic acid
high homology
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910279715.8A
Other languages
English (en)
Chinese (zh)
Inventor
D·B·韦纳
严健
N·Y·萨德赛
B·费拉罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Inovio Pharmaceuticals Inc
Original Assignee
University of Pennsylvania Penn
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn, Inovio Pharmaceuticals Inc filed Critical University of Pennsylvania Penn
Publication of CN110195069A publication Critical patent/CN110195069A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • A61K39/015Hemosporidia antigens, e.g. Plasmodium antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/195Chemokines, e.g. RANTES
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/208IL-12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2086IL-13 to IL-16
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445Plasmodium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55522Cytokines; Lymphokines; Interferons
    • A61K2039/55527Interleukins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Body Structure For Vehicles (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201910279715.8A 2010-09-27 2011-09-27 共有抗原构建体和由其制备的疫苗以及使用所述疫苗治疗疟疾的方法 Pending CN110195069A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38697310P 2010-09-27 2010-09-27
US61/386,973 2010-09-27
CN2011800513670A CN103354750A (zh) 2010-09-27 2011-09-27 共有抗原构建体和由其制备的疫苗以及使用所述疫苗治疗疟疾的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2011800513670A Division CN103354750A (zh) 2010-09-27 2011-09-27 共有抗原构建体和由其制备的疫苗以及使用所述疫苗治疗疟疾的方法

Publications (1)

Publication Number Publication Date
CN110195069A true CN110195069A (zh) 2019-09-03

Family

ID=45928328

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011800513670A Pending CN103354750A (zh) 2010-09-27 2011-09-27 共有抗原构建体和由其制备的疫苗以及使用所述疫苗治疗疟疾的方法
CN201910279715.8A Pending CN110195069A (zh) 2010-09-27 2011-09-27 共有抗原构建体和由其制备的疫苗以及使用所述疫苗治疗疟疾的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2011800513670A Pending CN103354750A (zh) 2010-09-27 2011-09-27 共有抗原构建体和由其制备的疫苗以及使用所述疫苗治疗疟疾的方法

Country Status (10)

Country Link
US (1) US10799572B2 (enExample)
EP (1) EP2621540A4 (enExample)
JP (1) JP6293485B2 (enExample)
KR (2) KR101891195B1 (enExample)
CN (2) CN103354750A (enExample)
AU (1) AU2011312465B2 (enExample)
BR (1) BR112013007051A2 (enExample)
CA (1) CA2812789A1 (enExample)
MX (1) MX355501B (enExample)
WO (1) WO2012047679A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2796147A1 (en) * 2013-04-24 2014-10-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel vaccines against apicomplexan pathoges
EP2923709A1 (en) * 2014-03-28 2015-09-30 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Multi-component-multistage malaria vaccine
EP2992895A1 (en) * 2014-09-08 2016-03-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Three-component-multistage malaria vaccine
CN105628928A (zh) * 2014-11-11 2016-06-01 深圳国际旅行卫生保健中心 可用于辅助诊断疟疾的试剂盒
EP3247390A4 (en) * 2015-01-23 2018-03-07 The Trustees Of The University Of Pennsylvania Immunogenicity of an optimized synthetic consensus dna vaccine for porcine epidemic diarrhea virus
EP3081575A1 (en) * 2015-04-12 2016-10-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-plasmodium parasite antibodies
US12398184B2 (en) 2016-11-01 2025-08-26 Washington University Compositions comprising CelTOS immunogens and antibodies and method of use thereof
WO2018156106A1 (en) * 2017-02-22 2018-08-30 Ding Enyu An mrna cancer vaccine encoding human gm-csf fused to multiple tandem epitopes
CN109125740B (zh) * 2017-06-28 2022-04-05 成都威斯克生物医药有限公司 一种新型的肿瘤疫苗及其用途
KR102169664B1 (ko) * 2019-02-26 2020-10-23 원광대학교산학협력단 열대열말라리아원충 유래의 EF-1α 재조합 단백질을 유효성분으로 포함하는 말라리아 예방용 백신 조성물
WO2022204597A1 (en) * 2021-03-26 2022-09-29 David Weiner Dna encoded nanoparticle vaccine against human papillomavirus, and methods of use thereof
WO2025024337A1 (en) * 2023-07-24 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
DE69434469T2 (de) 1993-01-26 2006-06-14 Univ Pennsylvania Zusammensetzungen und verfahren zur verabreichung von genetischem material
CA2285056C (en) 1997-04-03 2004-12-14 Iacob Mathiesen Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
JP2002507985A (ja) 1997-06-30 2002-03-12 ローヌ−プーラン・ロレ・エス・アー 横紋筋に核酸を導入する改良法およびその組合せ
US6697669B2 (en) 1998-07-13 2004-02-24 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
AU2003298361B2 (en) 2002-12-17 2009-05-14 Crucell Holland B.V. Recombinant viral-based malaria vaccines
TWI303275B (en) 2003-05-30 2008-11-21 Advisys Inc Devices and methods for biomaterial production
US7981601B2 (en) 2003-08-01 2011-07-19 Institute Of Basic Medical Sciences Method of preparing polyepitope chimeric gene vaccine
US8168166B2 (en) * 2003-12-19 2012-05-01 Seattle Biomedical Research Institute Live genetically attenuated malaria vaccine
CA2620495A1 (en) * 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
JP5508266B2 (ja) * 2007-08-13 2014-05-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
CN105535961A (zh) 2008-04-04 2016-05-04 宾夕法尼亚大学托管会 使用il-28和组合物的疫苗和免疫治疗及其使用方法
WO2010062859A2 (en) * 2008-11-25 2010-06-03 United States Department Of The Army, As Respresented By The Secretary Of The Army Recombinantly expressed plasmodium celtos antigen and methods of use thereof
US20110229514A1 (en) * 2009-03-16 2011-09-22 Denise Doolan Vaccine and immunization method using plasmodium antigen 2

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALYSSA E. BARRY等: "Contrasting Population Structures of the Genes Encoding Ten Leading Vaccine-Candidate Antigens of the Human Malaria Parasite,Plasmodium falciparum", 《POLSONE》 *
FERRARO等: "A Novel Multi-Antigen DNA-Based Malaria Vaccine Candidate Delivered by Electroporation Induces Potent Humoral and Cellular Responses", 《THE THIRTEENTH ANNUAL CONFERENCE ON VACCINE RESEARCH》 *
P.GIRARD 等: "A review of human vaccine research and development:Malaria", 《VACCINE》 *

Also Published As

Publication number Publication date
WO2012047679A8 (en) 2012-08-16
AU2011312465A1 (en) 2013-05-02
JP2013543721A (ja) 2013-12-09
US10799572B2 (en) 2020-10-13
WO2012047679A2 (en) 2012-04-12
KR20180096814A (ko) 2018-08-29
MX355501B (es) 2018-04-20
EP2621540A2 (en) 2013-08-07
US20130273112A1 (en) 2013-10-17
KR20130138790A (ko) 2013-12-19
KR101891195B1 (ko) 2018-08-24
AU2011312465B2 (en) 2015-07-23
CA2812789A1 (en) 2012-04-12
MX2013003470A (es) 2013-08-01
EP2621540A4 (en) 2014-08-27
BR112013007051A2 (pt) 2019-07-02
CN103354750A (zh) 2013-10-16
WO2012047679A3 (en) 2012-06-14
JP6293485B2 (ja) 2018-03-14

Similar Documents

Publication Publication Date Title
KR101891195B1 (ko) 공통 항원 구성체 및 이것으로부터 만들어진 백신 및 말라리아를 치료하기 위한 이것의 사용방법
KR102581951B1 (ko) B형 간염 바이러스 코어 단백질 및 표면 항원 단백질 및 이를 포함하는 백신
AU2016202122B2 (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
CN101877965B (zh) 针对流感病毒的多种亚型的疫苗
AU2017214656B2 (en) Cancer vaccines and methods of treatment using the same
DK2538972T3 (en) RECOMBINANT CDV COMPOSITIONS AND APPLICATIONS THEREOF
KR20160102024A (ko) 아데노바이러스 및 상응하는 플라스미드의 제조 방법
JP2011115178A (ja) 3つの完全な転写単位を有するプラスミドおよびhivに対する免疫応答を誘発するための免疫原組成物
KR20200130339A (ko) 사람 파필로마바이러스 백신 및 이의 용도
CN114106207B (zh) Ccl5的用途
KR20150128900A (ko) 항원 및 어쥬번트로서 인터류킨-23을 갖는 백신
KR20230087583A (ko) 항원을 mhc-ii 경로로 전달하고 숙주에서 cd4+ 및 cd8+ t-세포 반응을 유도하는 새로운 세대의 렌티바이러스 벡터
CA2429708A1 (en) Nucleic acid adjuvants
KR20200128703A (ko) B형 간염 백신 및 이의 용도
CN103083660B (zh) 一种用于弓形虫感染预防的免疫佐剂及其应用
ES2270120T3 (es) Vacuna contra infecciones causadas por oncovirus tales como el virus de la leucemia felina.
CN108410901B (zh) 无抗性筛选双抗原锚定表达载体pLQ2a及制备方法
US20030162733A1 (en) Nucleic acid adjuvants
CN100431612C (zh) 一种乙肝核酸疫苗、其制备方法及其应用
RU2760984C1 (ru) Противораковые вакцины, направленные на lemd1, и их применение
HK1246318B (en) Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
HK1262085A1 (en) Cancer vaccines and methods of treatment using the same
HK40034680A (en) Cancer vaccines targeting lemd1 and uses thereof
HK1149176B (en) Vaccines against multiple subtypes of influenza virus

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190903